Cardinal Health’s Strong Pharmaceutical Performance and Strategic Growth Drive Buy Rating
Bank of America Securities analyst Allen Lutz maintained a Buy rating on Cardinal Health (CAH – Research Report) yesterday and set a price ...
Cardinal Health’s Strong Pharma and Specialty Growth Justifies Buy Rating and Raised EPS Guidance
Mizuho Securities analyst Steven Valiquette has maintained their bullish stance on CAH stock, giving a Buy rating on January 10.Stay Ahead of ...